About

I am an award-winning writer, editor, photographer and designer with more than 30 years of experience in the media. After studying at the University of Leeds, then London and Anglia HEC, I moved to Canada in the 1980s and started out on the radio while also writing for various music and sports publications, and doing freelance photography. I then edited some magazines before working at a science organization, doing communications and editing publications in a programming language called LaTeX that was challenging but exciting.

Following that, I edited a newspaper, spent some time in the US, and then moved back to the UK where I edited a food B2B publication.
I’ve written, and taken photographs for, hundreds of publications around the world, as well as for books, album covers, DVDs, and shot coverage for documentaries. I’ve edited books, written nine of my own, and done redesigns for several publications. And now I’m writing about biotech, as well as creating videos and a weekly podcast.

I’ve done other things, like running an aquarium, teaching photography and drumming (not at the same time), and running football (soccer) refereeing courses.

In what spare time I have, I love spending time with my wife, son and dog, challenging hikes up the Scottish hills (and down again), playing and writing music, watching baseball and soccer, and collecting memorabilia and autographs.

Articles by Jim Cornall

CytoReason expands deal with Sanofi to look at IBD

Interview 24 Jan 2023

Watch: Queen’s University tackling antimicrobial resistance

Interview 23 Jan 2023

Watch: pHion Therapeutics talks about next-generation mRNA vaccines

Beyond Biotech podcast 30: Advanced Therapies Congress, BioAlps, Bionter, C2i Genomics 

Aldevron launches type-V CRISPR Nuclease

New drug could replace current standard for treating brain cancer 

ADVERTISEMENT

DeuterOncology closes financing round to start lung cancer study

Brenus Pharma and InSphero bag €1.5M for next-generation cancer cell immunotherapy 

Netherlands Cancer Institute to use Proscia platform

Cloned maggot enzyme wound treatment moves closer to reality

Avacta completes fourth dose escalation in tumor study

GPCR Therapeutics launches multiple myeloma trial

ADVERTISEMENT